Transcenta Sells Hangzhou GMP Plant to WuXi Biologics for $26.2M
- Transcenta divests its Hangzhou GMP manufacturing facility, land, equipment, and staff to WuXi Biologics for RMB 190 million, closing by end-2026.
- Transcenta retains HiCB bioprocessing platform and ExcelPro CHO media IP; will outsource future manufacturing to third parties while focusing on drug pipeline and technology licensing.
- Proceeds fund advancement of osemitamab into global Phase III trials for gastric cancer and reduce near-term cash burn without equity dilution.
Operational Impact
WuXi Biologics acquires an operational GMP facility in Hangzhou with existing manufacturing contracts and staff, expanding its China-based drug-product capacity while Transcenta shifts to outsourced manufacturing partnerships.
Source: PharmaSource RSS
Gland Pharma Wins $90M–$100M Sterile Injectable Manufacturing Deal
- Gland Pharma secured a Manufacturing and Supply Agreement covering 55 sterile injectable SKUs for a global pharmaceutical company, with commercial revenue expected to begin in 2029.
- The deal is projected to generate $90 million–$100 million in annualized revenue once fully commercialized, leveraging three of Gland Pharma's facilities.
- Technology transfer and process development will be completed within two years, with Gland Pharma providing full-service CDMO support including manufacturing, quality, and regulatory services.
Operational Impact
Gland Pharma's three-facility sterile injectable footprint gains $90M–$100M in committed annualized revenue and multi-year technology-transfer visibility, strengthening its CDMO capacity utilization and long-term commercial pipeline.
Source: PharmaSource RSS